{
  "candidate_id": "CAND_20251022205141178330",
  "name": "Agnew, Jonathan",
  "role_category": "Validation",
  "titles": [
    "Validation"
  ],
  "skills": [
    {
      "name": "go",
      "confidence": 0.7
    },
    {
      "name": "rust",
      "confidence": 0.7
    },
    {
      "name": "react",
      "confidence": 0.9
    },
    {
      "name": "spring",
      "confidence": 0.7
    },
    {
      "name": "gcp",
      "confidence": 0.7
    },
    {
      "name": "communication",
      "confidence": 0.7
    },
    {
      "name": "analytical",
      "confidence": 0.9
    }
  ],
  "experience_years": 4,
  "education": [
    {
      "degree": "ms",
      "field": "CRO  Contract Research Organization  \nCSR  Clinical Study Report  \nEDC  Electronic Data Capture  \nFDA Food and Drug Administration  \nGCP  Good Clinical Pract ice \nHPLC  High"
    },
    {
      "degree": "ms",
      "field": "to ensure \nclarity"
    },
    {
      "degree": "ms",
      "field": "were systematically stored in individual \nparticipant study files"
    },
    {
      "degree": "M.D.",
      "field": "Dr"
    },
    {
      "degree": "ms",
      "field": "rather than the underlying \ndisease mechanisms"
    },
    {
      "degree": "ms",
      "field": "both efficacy \nand safety"
    },
    {
      "degree": "ms",
      "field": "in patients using the Neuropsychiatric \nInventory"
    },
    {
      "degree": "ms",
      "field": "Alzheimer"
    },
    {
      "degree": "ms",
      "field": "post"
    },
    {
      "degree": "ma",
      "field": "and improvement in MMSE and ADAS \nscores"
    },
    {
      "degree": "ma",
      "field": "was occasionally assessed to further ensure compliance"
    },
    {
      "degree": "ma",
      "field": "concentrations of NeuroZel typically \ndemonstrated better cognitive test scores"
    },
    {
      "degree": "ms",
      "field": "A D"
    },
    {
      "degree": "Ph.D.",
      "field": "Report Vers ion Number"
    },
    {
      "degree": "Ph.D.",
      "field": "Brain and Neurological Research Center"
    },
    {
      "degree": "Ph.D.",
      "field": "Dr"
    },
    {
      "degree": "Ph.D.",
      "field": "Dr"
    }
  ],
  "contact": {
    "email": null,
    "phone": null,
    "linkedin": null,
    "location": " Boston, MA 02110"
  },
  "email": null,
  "phone": null,
  "location": " Boston, MA 02110",
  "work_authorization": null,
  "availability": null,
  "resume_snippet": "Summary and Co nclusions: Efficacy Results : Primary End point(s): Significant improvement in ADAS -Cog scores in the NeuroZel group compared to placebo. Secondary End points(s) : Improved quality of life as evidenced by higher ADCS -ADL scores in the NeuroZel group compared to placebo. Exploratory Endpo int(s): Decreased caregiver burden in the NeuroZel group as reported through caregiver surveys. CCR 00-0001 CSR Version 1.0 Date 17-Aug-2023 Page 6 of 37 Safety Results: NeuroZel was well -toler",
  "source_file": "/Users/swetchareddy/Desktop/Recruiting/OneDrive_1_9-22-2025/AVS CV's/Validation/Agnew, Jonathan/Sample Clinical Study Report.pdf",
  "parsed_date": "2025-10-22T20:51:41.178344",
  "status": "New",
  "stage": "Uploaded"
}